41 results about "Hepatic ischemia" patented technology

The invention relates to a medicinal composition for treating an ischemia reperfusion injury, particularly a hepatic ischemia reperfusion injury, and a preparation method and application thereof. The composition comprises an M-cholinergic receptor blocker and a cholinesterase inhibitor, has a simple and convenient preparation process, is safe to use, has an obvious curative effect, can be used for obviously improving the cell apoptosis caused by the ischemia reperfusion injury and overcomes the side effects caused by existing common medicaments. The invention expands novel medical application of an existing muscarinic receptor blocker and also provides a novel medicine intervention means for preventing and treating the ischemia reperfusion injury. The medicinal composition is suitable for large-scale production and commercial application in the industries of medicine, reagents and the like, has excellent application prospect and has obvious social benefits and economic benefits.

The invention discloses a gene Mindin and an application of an inhibitor thereof in a hepatic ischemia reperfusion injury, and belongs to the field of functions and applications of genes. After the experiment is carried out through a hepatic ischemia reperfusion injury model by taking a gene Mindin knockout rat and a Mindin transgenosis rat with a hepatic cell specificity as experimental subjects, the result shows that the hepatic necrosis of the gene Mindin knockout rat is obviously inhibited and the hepatic function of the gene Mindin knockout rat is obviously improved in comparison with a wild-type C57 rat, but the hepatic necrosis of the Mindin transgenosis rat with the hepatic cell specificity is obviously increased and the hepatic function of the hepatic necrosis Mindin transgenosis rat is seriously deteriorated. Thus, the gene Mindin has a function of deteriorating hepatic cells, especially, the gene Mindin has the function of deteriorating the hepatic ischemia reperfusion injury. Aiming at the function of the gene Mindin, the gene Mindin can serve as a medicine target for screening medicines for treating the hepatic ischemia reperfusion injury. The inhibitor of the gene Mindin can be used for preparing the medicines for treating the hepatic ischemia reperfusion injury.

The invention provides a penthorum chinense pursh extract. The HPLC finger-print is characterized by comprising four characteristic peaks, wherein the retention time of the first peak is 10.4+ / -0.25 min, and the peak area of the first peak is 1682000+ / -8000; the retention time of the second peak is 12.5+ / -0.25 min, and the peak area of the second peak is 36750+ / -700; the retention time of the third peak is 13.0+ / -0.25 min, and the peak area of the third peak is 2461000+ / -3000; the retention time of the fourth peak is 14.9+ / -0.25 min, and the peak area of the fourth peak is 1831000+ / -5000. The treatment effect of the penthorum chinense pursh extract is excellent in treating hepatic ischemia reperfusion liver injuries and chemical liver injuries and has broad clinical application prospects.

The invention provides an application of pinocembrin dihydrogen chalcone-7-O-[3'-O-galloyl-4',6'-hexahydroxydiphenodicarboxy]-beta-D-glucoside in preparation of a liver protection medicine. The penthorum chinense pursh macrocyclic polyphenol monomer namely pinocembrin dihydrogen chalcone-7-O-[3'-O-galloyl-4',6'-hexahydroxydiphenodicarboxy]-beta-D-glucoside has a liver protection effect, can be used for preventing and treating liver injuries, and has a definite curative effect on hepatic ischemia-reperfusion injuries and chronic liver injuries, and the effect is superior to that of positive medicine namely Gansu Granules, so that the penthorum chinense pursh macrocyclic polyphenol monomer can be used for replacing the Gansu Granules and has a good clinical application prospect.

The invention discloses application of Mincle and an inhibitor thereof in hepatic ischemia reperfusion injuries, and belongs to the function and application field of genes. A hepatic cell specific Mincle gene knockout mouse and a Mincle transgenic mouse as experimental subjects, the functions of a Mincle gene are researched by virtue of a hepatic ischemia reperfusion injury model, and the Mincle gene is discovered to have an effect of exacerbating liver functions, so that the Mincle has the following applications: application of the Mincle serving as a drug target in screening medicines for preventing, relieving and / or treating the hepatic ischemia reperfusion injuries or protecting the liver functions, wherein screening the medicines for preventing, relieving and / or treating the hepatic ischemia reperfusion injuries or protecting the liver functions refers to screening the medicines capable of inhibiting Mincle expression, and application of the inhibitor of the Mincle in preparation of the medicines for preventing, relieving and / or treating the hepatic ischemia reperfusion injuries or protecting the liver functions.

The invention relates to an application of caffeic acid in preparation of drugs for treating hepatic microcirculation disturbance and hepatic injury. Through a series of observation of caffeic acid on hepatic ischemia reperfusion rats, caffeic acid is found to improve the hepatic surface blood flow quantity by the action routes: AMPK[alpha] phosphorylation and PKC[delta] membrane translocation are inhibited, NADPH subunit P41 and P47 membrane translocation is inhibited and NADPH-derived peroxides are inhibited; the activity of a hepatic ischemia reperfusion rat mitochondria respiratory chain is improved, and peroxide production caused by mitochondria injury is reduced, so as to increase the production of ATP; hepatocyte apoptosis caused by ischemia reperfusion is inhibited; and hepatic cell internal cytoskeleton injury caused by ischemia reperfusion is attenuated. The new application in preparation of the drugs for treating hepatic microcirculation disturbance and hepatic injury is provided.

The invention relates to a novel cocktail probe medicament combination comprising caffeine, metoprolol, chlorzoxazone, tolbutamide and midazolam. The influence of hepatic ischemia preconditioning and hepatic ischemia-reperfu-sion injury on medicament metabolism activity of rat CYP1A2, CYP2C9, CYP2E1, CYP2D6, and CYP3A4 in vivo is evaluated through the change of pharmacokinetics parameters of the combination.

The invention discloses a polypeptide substance, preparation method and application thereof. The invention also discloses extraction process of two polypeptides, and determines molecular weight and amino acid sequence of the polypeptides. The polypeptides are synthesized by the chemical method, and purity analysis and molecular weight measurement results of the polypeptides indicate that molecular ion peak (m / z) completely satisfies theoretical molecular weight. Amino acid analysis result of the polypeptides indicates that amino acid content and the composition of the peptides are in accordance with theoretical values. Amino acid sequence measurement result of the polypeptides indicates primary structure thereof is in accordance with the designed sequence. At the same time, activity measurement result of the polypeptides indicates that the two peptides have activity, and remarkable effect on the treatment of myocardial ischemia, cerebral ischemia, and hepatic ischemia.

The invention provides application of arachidonate lipoxygenase (ALOX)12 inhibitor to preparation of a heart ischemia reperfusion injury (IRI) therapeutic drug. Through research, it is found that in hepatic ischemia reperfusion injury (HIRI), the ALOX12 protein expression quantity and the mRNA expression quantity are changed significantly, the change of ALOX5 and the change of ALOX15 have no difference, and it shows that compared with other ALOX members, the ALOX12 has the larger effect on the HIRI; through ALOX12 overexpression, activity decreasing of liver cells and kidney cells due to anaerobic and reoxygenation treatment is aggravated, and an inflammatory reaction of the liver cells is promoted; and through ALOX12 under-expression, activity decreasing of cardiac muscle cells due to anaerobic and reoxygenation treatment can be relieved, and the results show that the ALOX12 can promote IRI of organs such as the liver, the heart and the kidney, and occurrence and development of otherinflammatory reactions in the organs. On the basis, the ALOX12 can serve as a treatment target point of the IRI, IRI-related diseases, inflammatory diseases and cell death-related diseases.

The invention discloses application of human sDR5-Fc recombinant fusion protein in preparation of drugs for preventing and treating liver ischemia-reperfusion injury. The nucleotide sequence for encoding the sDR5-Fc recombinant fusion protein has a) a base sequence shown in SEQ ID NO: 1, or b) a complementary pairing sequence with SEQ ID NO: 1, or c) a sequence which encodes the same sequence as the nucleotide sequence of a or b but is different from the nucleotide sequence of a or b due to the degeneracy of genetic codes; or the amino acid sequence of the sDR5-Fc recombinant fusion protein isshown in SEQ ID NO: 2, or the amino acid sequence is shown in SEQ ID NO: 2, and one or more amino acids are substituted, but the biological activity is not changed; or the amino acid sequence of thesDR5-Fc recombinant fusion protein is shown in SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 or SEQ ID NO: 6.

The invention provides an application of magnesium lithospermate B or a pharmaceutical composition containing the lithospermate B in preparation of a medicine. The medicine is used for treating and / orpreventing liver injury, especially liver injury caused by hepatic ischemia reperfusion. According to the invention, a mouse hepatic ischemia reperfusion animal model is utilized to systematically prove the treatment and protection effects of the magnesium lithospermate B or the pharmaceutical composition containing the magnesium lithospermate B, such as salvianolate, on hepatic ischemia reperfusion for the first time, the internal mechanism of the medicine is clarified, and a theoretical basis is provided for clinical application.

The invention provides a liver perfusate, which is prepared by 5,500 to 6,500 mg / L of sodium chloride, 250 to 350 mg / L of potassium chloride, 150 to 250 mg / L of calcium chloride, 3,000 to 3,200 mg / L of sodium lactate, 4 to 6 mmol / L of 1, 6-diphosphofructose, 5 to 15 mg / L of dexamethasone, 2.5 to 3.5 mmol / L of reduced glutathione, and 4 to 6mg / L of verapamil. The product has a simple formula, convenient configuration, low cost and proper potassium concentration, can be safely used for the preservation of isolated organs, more importantly can be applied to the perfusion protection of in vivo organs, and can effectively prevent the injury of hepatic ischemia reperfusion. The invention also provides two preparation methods for the liver perfusate.

The invention discloses application of an inhibitor of TRAF1 (TNF Receptor Associated Factor 1) to liver ischemic disease, belonging to the field of biomedicines. A TRAF1 gene knock-out mouse and a hepatocyte specific TRAF1 transgenic mouse are taken as experimental objects, and a hepatic ischemia reperfusion injury model is adopted. As proved by a result, the hepatic necrosis of the TRAF1 gene knock-out mouse is inhibited remarkably and the liver function is improved remarkably in comparison to those of a wild C57 mouse while the hepatic necrosis of the hepatocyte specific TRAF1 transgenic mouse is increased remarkably and the liver function deteriorates remarkably. Thus, the TRAF1 gene has the effect of deteriorating the liver function, and can particularly deteriorate liver ischemic disease. Aiming at the functions of the TRAF1, application of the TRAF1 as a medicinal target in treatment of liver ischemic disease to the preparation of medicaments for treating liver ischemic disease is provided.

The invention discloses an application of USP10 in hepatic ischemia reperfusion injury. A USP10 gene knockout mouse and a C57BL / 6 wild type mouse are selected as experimental subjects, mouse hepatic ischemia reperfusion injury models are constructed respectively, the function of USP10 in hepatic ischemia reperfusion injury is researched, the new function of the USP10 gene in hepatic ischemia reperfusion injury is found, and the application of the USP10 gene in hepatic ischemia reperfusion injury is developed. The over-expression of the USP10 can relieve the hepatic ischemia reperfusion injury by inhibiting inflammation and cell apoptosis, so that the USP10 can be applied to the preparation of the medicine for preventing / treating the hepatic ischemia reperfusion injury, and a new medicine target is provided for the hepatic ischemia reperfusion injury.

The invention relates to an application of a compound with the tail end being branched chain fatty acid and a compound of a derivative for preparing medicine curing ischemia and reperfusion injury of tissues or organs of people. The ischemia and reperfusion injury comprises cerebral ischemia and reperfusion injury caused by operations of cerebrovascular disorder, cardiac arrest and cardio-pulmonary resuscitation, and ischemia and reperfusion injury of therapy of miocardial infarction, ischemia of intestine, hepatic ischemia and thrombolysis, operations on vessels of heart, and histoorgan transplantation.

The present disclosure provides a method of treating or preventing hepatic ischemia and reperfusion injury in an animal comprising administering an effective amount of an FGL2-FcγRIIB inhibitor to an animal in need thereof. Also provided herein are uses, compositions and screening assays for FGL2- FcγRIIB inhibitors useful in treating hepatic ischemia and reperfusion injury.

The invention provides an application of methyleugenol in preparation of a medicine for relieving hepatic ischemia-reperfusion injury. The methyleugenol comprises a medicine composition containing the methyleugenol and various pharmaceutically acceptable medicine preparations of the methyleugenol, has a protection effect on the hepatic ischemia-reperfusion injury, can relieve injury. The application of the methyleugenol in preparation of the medicine for relieving the hepatic ischemia-reperfusion injury has clinical practical significance and value for further development and application.

The invention discloses a cascaded nano-enzyme as well as a preparation method and application thereof. The cascaded nano-enzyme comprises a metal organic framework carrier, nitric oxide synthetase combined with the metal organic framework carrier and platinum nanoparticles combined with the metal organic framework carrier. The cascaded nano-enzyme belongs to a nano size, has the natural advantage of passive accumulation in the liver compared with a small molecule drug, can increase the enrichment of the drug in the liver, and has higher targeting property. The platinum nanoparticles as the nano-enzyme have excellent reactive oxygen species (ROS) scavenging capacity and can catalyze the reactive oxygen to generate oxygen, the generated oxygen reacts with arginine under the catalysis of nitric oxide synthetase (iNOS) to generate NO in situ, and the bioavailability of NO is improved. Therefore, the cascaded nano-enzyme improves the targeting property and bioavailability of NO, and can simultaneously realize ROS scavenging and NO regulation, thereby realizing effective intervention on injury caused by liver ischemia reperfusion.

The invention provides a liver perfusate, which is prepared by 5,500 to 6,500 mg / L of sodium chloride, 250 to 350 mg / L of potassium chloride, 150 to 250 mg / L of calcium chloride, 3,000 to 3,200 mg / L of sodium lactate, 4 to 6 mmol / L of 1, 6-diphosphofructose, 5 to 15 mg / L of dexamethasone, 2.5 to 3.5 mmol / L of reduced glutathione, and 4 to 6mg / L of verapamil. The product has a simple formula, convenient configuration, low cost and proper potassium concentration, can be safely used for the preservation of isolated organs, more importantly can be applied to the perfusion protection of vivo organs, and can effectively prevent the injury of hepatic ischemia reperfusion. The invention also provides two preparation methods for the liver perfusate.

Provided is a novel use of ADAMTS13 in the medical field. Use of ADAMTS13 as a biomarker for monitoring the onset of hepatopathy, hepatic ischemia / reperfusion injury or hepatic function after liver transplantation; a method for examining hepatopathy, a method for examining hepatic ischemia / reperfusion injury or a method for examining hepatic function after liver transplantation, each method comprising measuring or monitoring ADAMTS13 activity in a sample obtained from a mammal; and a therapeutic agent for a disease selected from the group consisting of hepatopathy, hepatic ischemia / reperfusioninjury and hepatic dysfunction after liver transplantation, the agent comprising ADAMTS13 or a modification thereof.

The invention discloses application of syringaresinol in preparation of a medicine for preventing and treating liver ischemia-reperfusion injury, and belongs to the technical field of syringaresinol application. According to the present invention, the drug experiment research results show that the syringaresinol is the natural traditional Chinese medicine monomer, has the low toxic-side effect, can be used for preparing the liver ischemia-reperfusion injury prevention and treatment drug, opens up the new liver ischemia-reperfusion injury prevention and treatment drug, and opens up the new useof the syringaresinol so as to provide the broad market prospects. And great social significance and economic benefits are achieved.

The invention discloses application of heat shock factor 2 binding protein (HSF2BP) in liver ischemia reperfusion injury and drug-induced liver injury, and belongs to the field of gene functions and application. According to the invention, liver-specific HSF2BP gene overexpression and knockout mice are used as the experimental subject, a liver ischemia reperfusion injury model and a drug-induced liver injury model are used, the results show that compared with a wild C57 mouse, the liver injury of an HSF2BP gene overexpression mouse in the two models is obviously inhibited, the liver function is obviously improved, while the liver injury of an HSF2BP gene knockout mouse in the two models is obviously increased, and the liver function is obviously deteriorated. Therefore, the HSF2BP gene hasthe effect of protecting liver injury, and particularly has the effects of protecting ischemia reperfusion induced liver injury and drug-induced liver injury. Directed at the functions of HSF2BP, a specific agonist of the HSF2BP can be used for promoting HSF2BP gene expression so as to intervene in liver ischemia reperfusion injury and drug-induced liver injury.

The invention discloses application of L-malic acid in preparation of a medicine for preventing and treating liver ischemia-reperfusion injury, and particularly discloses application of the L-malic acid serving as a unique active ingredient in preparation of a medicine or a health care product for preventing or treating the liver ischemia-reperfusion injury. Mouse in-vivo experiments prove that the L-malate can significantly reduce the increase of hepatic injury markers such as alanine aminotransferase, aspartate aminotransferase and lactic dehydrogenase in serum caused by hepatic ischemia / reperfusion, and reduce the hepatic necrosis area; and meanwhile, liver tissue lipid peroxidation and cell ferroptosis caused by ischemia / reperfusion are inhibited, so that hepatic injury is relieved. The invention provides a theoretical basis for treatment of hepatic ischemia / reperfusion injury related diseases, and has clinical application value.

The invention discloses an application of Caspase recruitment domain protein 6 (Card6) in hepatic ischemia reperfusion injury and belongs to the field of functions and applications of genes. According to the application, hepatic-cell specific Card6 gene knockout mice and Card6 transgenic mice serve as experimental subjects, functions of a Card6 gene are researched through a hepatic ischemia reperfusion injury model, and the condition that Card6 plays a role in improving the hepatic ischemia reperfusion injury is discovered, so that the Card6 has the applications as follows: an application of the Card6 in screening of drugs for preventing, relieving and / or treating the hepatic ischemia reperfusion injury as a drug target, wherein the screening of the drugs for preventing, relieving and / or treating the hepatic ischemia reperfusion injury means screening the drugs capable of promoting Card6 expression; an application of the Card6 in preparation of drugs for preventing, relieving and / or treating the hepatic ischemia reperfusion injury.

The invention provides an application of pinocembrin dihydrogen chalcone-7-O-[3'-O-galloyl-4',6'-hexahydroxydiphenodicarboxy]-beta-D-glucoside in preparation of a liver protection medicine. The penthorum chinense pursh macrocyclic polyphenol monomer namely pinocembrin dihydrogen chalcone-7-O-[3'-O-galloyl-4',6'-hexahydroxydiphenodicarboxy]-beta-D-glucoside has a liver protection effect, can be used for preventing and treating liver injuries, and has a definite curative effect on hepatic ischemia-reperfusion injuries and chronic liver injuries, and the effect is superior to that of positive medicine namely Gansu Granules, so that the penthorum chinense pursh macrocyclic polyphenol monomer can be used for replacing the Gansu Granules and has a good clinical application prospect.

The invention discloses the application of a TRAF1 inhibitor in liver ischemic diseases, and belongs to the field of biomedicine. In the present invention, TRAF1 gene knockout mice and hepatocyte-specific TRAF1 transgenic mice are used as experimental objects, and the hepatic ischemia-reperfusion injury model is used. The results show that compared with wild-type C57 mice, TRAF1 gene knockout mice have obvious liver necrosis Inhibited, liver function also significantly improved, while hepatic cell-specific TRAF1 transgenic mice had significantly increased liver necrosis and significantly worsened liver function. Therefore, TRAF1 gene has the effect of deteriorating liver function, especially TRAF1 gene can aggravate hepatic ischemic disease. According to the above functions of TRAF1, TRAF1 is provided as a drug target for the treatment of liver ischemic diseases and applied in the development of drugs for liver ischemic diseases.

The present invention finds through research that in liver ischemia-reperfusion injury, the changes of ALOX12 protein expression and mRNA expression are significant, while the changes of ALOX5 and ALOX15 have no difference, indicating that compared with other ALOX members, ALOX12 has a greater effect on liver ischemia-reperfusion injury. The effect of perfusion injury was greater. The overexpression of ALOX12 will aggravate the decreased activity of liver cells and kidney cells caused by hypoxia and reoxygenation, and promote the inflammatory response of liver cells; and the low expression of ALOX12 can alleviate the decreased activity of cardiomyocytes caused by hypoxia and reoxygenation, these The results show that ALOX12 can promote ischemia-reperfusion injury in organs such as liver, heart and kidney, as well as the development of other inflammatory responses in these organs. On this basis, ALOX12 can be used as a therapeutic target for ischemia-reperfusion injury and related diseases, as well as inflammatory diseases and cell death-related diseases.

The present invention discloses a new application of hydroxychloroquine. The hydroxychloroquine is used for preparing medicines for treating hepatic ischemia reperfusion injury. According to the new application of the hydroxychloroquine, by inhibiting the generation of neutrophil extracellular traps (nets), the good treatment effect can be taken for the hepatic ischemia reperfusion injury, so thatthe injury area of the liver is reduced.

The invention discloses an application of Caspase recruitment domain protein 6 (Card6) in hepatic ischemia reperfusion injury and belongs to the field of functions and applications of genes. According to the application, hepatic-cell specific Card6 gene knockout mice and Card6 transgenic mice serve as experimental subjects, functions of a Card6 gene are researched through a hepatic ischemia reperfusion injury model, and the condition that Card6 plays a role in improving the hepatic ischemia reperfusion injury is discovered, so that the Card6 has the applications as follows: an application of the Card6 in screening of drugs for preventing, relieving and / or treating the hepatic ischemia reperfusion injury as a drug target, wherein the screening of the drugs for preventing, relieving and / or treating the hepatic ischemia reperfusion injury means screening the drugs capable of promoting Card6 expression; an application of the Card6 in preparation of drugs for preventing, relieving and / or treating the hepatic ischemia reperfusion injury.